Ana Carrizosa Anderson

List of Publications by Year
in descending order

Version: 2024-02-01

97 papers	17,501 citations	34076 52 h-index	46771 89 g-index
107 all docs	107 docs citations	107 times ranked	19975 citing authors

#	Article	IF	Citations
1	The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunology, 2005, 6, 1245-1252.	7.0	1,697
2	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2010, 207, 2187-2194.	4.2	1,652
3	Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 2016, 44, 989-1004.	6.6	1,538
4	Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14733-14738.	3.3	697
5	Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells. Science, 2007, 318, 1141-1143.	6.0	623
6	Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 2011, 117, 4501-4510.	0.6	554
7	TIM3 comes of age as an inhibitory receptor. Nature Reviews Immunology, 2020, 20, 173-185.	10.6	535
8	CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature, 2015, 517, 386-390.	13.7	525
9	TIGIT predominantly regulates the immune response via regulatory T cells. Journal of Clinical Investigation, 2015, 125, 4053-4062.	3.9	470
10	Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1â^'CD8+ Tumor-Infiltrating T Cells. Immunity, 2019, 50, 181-194.e6.	6.6	424
11	Role of Th1 and Th17 cells in organ-specific autoimmunity. Journal of Autoimmunity, 2008, 31, 252-256.	3.0	371
12	<scp>TIGIT</scp> and <scp>CD</scp>96: new checkpoint receptor targets for cancer immunotherapy. Immunological Reviews, 2017, 276, 112-120.	2.8	351
13	T CELL RESPONSE IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE): Role of Self and Cross-Reactive Antigens in Shaping, Tuning, and Regulating the Autopathogenic T Cell Repertoire. Annual Review of Immunology, 2002, 20, 101-123.	9.5	336
14	Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature, 2018, 558, 454-459.	13.7	336
15	Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunology Research, 2014, 2, 410-422.	1.6	322
16	A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell, 2016, 166, 1500-1511.e9.	13.5	315
17	CD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2007, 179, 5228-5237.	0.4	313
18	Bat3 promotes T cell responses and autoimmunity by repressing Tim-3â€“mediated cell death and exhaustion. Nature Medicine, 2012, 18, 1394-1400.	15.2	303

#	Article	IF	Citations
19	Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape. Cancer Immunology Research, 2014, 2, 393-398.	1.6	278
20	Spatially organized multicellular immune hubs in human colorectal cancer. Cell, 2021, 184, 4734-4752.e20.	13.5	256
21	High Frequency of Autoreactive Myelin Proteolipid Proteinâ€“Specific T Cells in the Periphery of Naive Mice. Journal of Experimental Medicine, 2000, 191, 761-770.	4.2	254
22	TIM3⁺FOXP3⁺regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology, 2013, 2, e23849.	2.1	251
23	Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells. Immunity, 2014, 41, 270-282.	6.6	249
24	Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells. Journal of Immunology, 2010, 185, 1383-1392.	0.4	243
25	Tim-3 finds its place in the cancer immunotherapy landscape. , 2020, 8, e000911.		237
26	Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends in Immunology, 2011, 32, 345-349.	2.9	215
27	IL-1Î² Promotes Antimicrobial Immunity in Macrophages by Regulating TNFR Signaling and Caspase-3 Activation. Journal of Immunology, 2013, 190, 4196-4204.	0.4	180
28	PD-1 and Tim-3 Regulate the Expansion of Tumor Antigenâ€“Specific CD8+ T Cells Induced by Melanoma Vaccines. Cancer Research, 2014, 74, 1045-1055.	0.4	179
29	Tim-3, a negative regulator of anti-tumor immunity. Current Opinion in Immunology, 2012, 24, 213-216.	2.4	175
30	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer Discovery, 2019, 9, 1754-1773.	7.7	173
31	An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nature Communications, 2015, 6, 6072.	5.8	169
32	TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature, 2021, 595, 101-106.	13.7	169
33	Tim3 binding to galectin-9 stimulates antimicrobial immunity. Journal of Experimental Medicine, 2010, 207, 2343-2354.	4.2	165
34	T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8706-8711.	3.3	163
35	TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. PLoS Pathogens, 2016, 12, e1005490.	2.1	147
36	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26.	13.5	125

#	Article	IF	Citations
37	New roles for TIM family members in immune regulation. Nature Reviews Immunology, 2008, 8, 577-580.	10.6	121
38	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
39	Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. Journal of Immunology, 2018, 200, 3000-3007.	0.4	118
40	Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. Journal of Experimental Medicine, 2007, 204, 1691-1702.	4.2	117
41	TIM-3 and Its Regulatory Role in Immune Responses. Current Topics in Microbiology and Immunology, 2010, 350, 1-15.	0.7	114
42	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clinical Cancer Research, 2021, 27, 276-287.	3.2	100
43	Tâ€bet, a Th1 transcription factor regulates the expression of Timâ€3. European Journal of Immunology, 2010, 40, 859-866.	1.6	98
44	Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. Immunity, 2020, 53, 658-671.e6.	6.6	98
45	TIM-4 Expressed on APCs Induces T Cell Expansion and Survival. Journal of Immunology, 2008, 180, 4706-4713.	0.4	96
46	TIM-3 in autoimmunity. Current Opinion in Immunology, 2006, 18, 665-669.	2.4	92
47	Immune checkpoints in central nervous system autoimmunity. Immunological Reviews, 2012, 248, 122-139.	2.8	90
48	T cell factor 1: A master regulator of the T cell response in disease. Science Immunology, 2020, 5, .	5.6	85
49	Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology, 2018, 7, e1385690.	2.1	80
50	The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. Journal of Neuroimmunology, 2007, 191, 51-60.	1.1	75
51	Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17280-17285.	3.3	66
52	Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Current Opinion in HIV and AIDS, 2014, 9, 439-445.	1.5	64
53	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
54	A Transgenic Model of Central Nervous System Autoimmunity Mediated by CD4+ and CD8+ T and B Cells. Journal of Immunology, 2012, 188, 2084-2092.	0.4	59

#	Article	IF	Citations
55	An IL-27-Driven Transcriptional Network Identifies Regulators of IL-10 Expression across T Helper Cell Subsets. Cell Reports, 2020, 33, 108433.	2.9	54
56	The Notch Regulator Numb Links the Notch and TCR Signaling Pathways. Journal of Immunology, 2005, 174, 890-897.	0.4	53
57	Molecular Dissection of CD8 + T-Cell Dysfunction. Trends in Immunology, 2017, 38, 567-576.	2.9	51
58	IL-10 Plays an Important Role in the Homeostatic Regulation of the Autoreactive Repertoire in Naive Mice. Journal of Immunology, 2004, 173, 828-834.	0.4	47
59	Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood, 2012, 120, 682-690.	0.6	47
60	Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice. Journal of Clinical Investigation, 2011, 121, 4303-4310.	3.9	46
61	Up-Regulation of Gene Related to Anergy in Lymphocytes Is Associated with Notch-Mediated Human T Cell Suppression. Journal of Immunology, 2007, 178, 6158-6163.	0.4	44
62	Tuning T cell activation threshold and effector function with cross-reactive peptide ligands. International Immunology, 2000, 12, 205-213.	1.8	40
63	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clinical Cancer Research, 2018, 24, 2574-2584.	3.2	40
64	Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight, 2020, 5, .	2.3	30
65	Expression of Self-antigen in the Thymus. Journal of Experimental Medicine, 2003, 198, 1627-1629.	4.2	29
66	Male sex chromosomal complement exacerbates the pathogenicity of Th17 cells in a chronic model of central nervous system autoimmunity. Cell Reports, 2021, 34, 108833.	2.9	29
67	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	3.9	25
68	Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Science Immunology, 2022, 7, eabm0631.	5.6	22
69	The Non-Obese Diabetic Mouse Strain as a Model to Study CD8+ T Cell Function in Relapsing and Progressive Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 541.	2.2	21
70	Autoantigen-Responsive T Cell Clones Demonstrate Unfocused TCR Cross-Reactivity toward Multiple Related Ligands: Implications for Autoimmunity. Cellular Immunology, 2000, 202, 88-96.	1.4	19
71	Cutting Edge: TheIdd3Genetic Interval Determines Regulatory T Cell Function through CD11b+CD11câ^' APC. Journal of Immunology, 2008, 181, 7449-7452.	0.4	18
72	PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nature Communications, 2021, 12, 4907.	5.8	18

#	Article	IF	Citations
73	Presence of <scp>Tim</scp>3⁺ and <scp>PD</scp>â€1⁺<scp>CD8</scp>⁺<scp>T</scp> cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features. Journal of Pathology, 2022, 257, 186-197.	2.1	13
74	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2011, 208, 1331-1331.	4.2	12
75	Modulation of CD4 co-receptor limits spontaneous autoimmunity when high-affinity transgenic TCR specific for self-antigen is expressed on a genetically resistant background. International Immunology, 2007, 19, 1235-1248.	1.8	10
76	Tim Protein Structures Reveal a Unique Face for Ligand Binding. Immunity, 2007, 26, 273-275.	6.6	10
77	Revolutionizing Cancer Immunology: The Power of Next-Generation Sequencing Technologies. Cancer Immunology Research, 2019, 7, 168-173.	1.6	10
78	Spatial determinants of CD8+ T cell differentiation in cancer. Trends in Cancer, 2022, 8, 642-654.	3.8	8
79	A T cell extrinsic mechanism by which IL-2 dampens Th17 differentiation. Journal of Autoimmunity, 2015, 59, 38-42.	3.0	7
80	Editorial: Tim-3 puts on the brakes. Journal of Leukocyte Biology, 2012, 91, 183-185.	1.5	6
81	Comment on â€œTim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infectionâ€• Journal of Immunology, 2014, 193, 467-467.	0.4	5
82	Endogenous T Cell Receptor Rearrangement Represses Aggressive Central Nervous System Autoimmunity in a TcR-Transgenic Model on the Non-Obese Diabetic Background. Frontiers in Immunology, 2019, 10, 3115.	2.2	5
83	The origin and regulation of autopathogenic T cells. Journal of Clinical Immunology, 2001, 21, 74-80.	2.0	4
84	New Clones on the Block. Immunity, 2019, 51, 606-608.	6.6	4
85	NRP1 cripples immunological memory. Nature Immunology, 2020, 21, 972-973.	7.0	4
86	Combination immunotherapy: Where do we go from here?. , 2015, 3, .		3
87	IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii106-ii106.	0.6	1
88	Abstract A10: A distinct gene module for T cell dysfunction uncoupled from T cell activation and controlled by metallothioneins. , 2017, , .		1
89	Up-Regulation of Grail Is Associated with Notch-Mediated Human T-Cell Suppression. Clinical Immunology, 2006, 119, S42.	1.4	0
90	Tim-3/Tim-3L Pathway as a Target for Restoring Effector Functions in Exhausted CD8 Lymphocytes in Tumors. Clinical Immunology, 2010, 135, S12.	1.4	0

#	Article	IF	Citations
91	Introduction to the Special Issue: Immuno-oncology. Seminars in Immunology, 2021, 52, 101483.	2.7	0
92	Abstract SY19-02: Role of the Tim-3 and PD-1 pathways in T cell exhaustion and antitumor immunity. , 2011, , .		0
93	Abstract B085: Combining transcriptomic profiling and genome engineering to dissect regulation of tumor immunology. , 2016, , .		0
94	Abstract 2727: The discovery and characterization of PTZ-201, a fully-human, high affinity, antagonistic anti-TIGIT monoclonal antibody. , 2018, , .		0
95	256â€…The TIGIT/CD226/CD155 axis and the effects of combining PD-1/PD-L1 blockade with TIGIT-targeting antibody therapy in syngeneic murine glioblastoma models. , 2021, 9, A277-A278.		0
96	641â€…Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer. , 2021, 9, A670-A670.		0
97	209â€…Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasoneâ€™s detrimental effects on immune checkpoint blockade in glioblastoma cancer. , 2020, , .		0